NCT00531596View on ClinicalTrials.gov

Evaluation of Adhesion and Dermal Tolerability of EMSAM

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

July 31, 2007

Conditions
Healthy
Interventions
DRUG

EMSAM (Selegiline Transdermal System) 6mg/24Hr

EMSAM 6mg/24HR

DRUG

EMSAM (Selegiline Transdermal System) 9mg/24Hr

EMSAM 9mg/24Hr

DRUG

EMSAM (Selegiline Transdermal System) 12mg/24hr

EMSAM 12mg/24Hr

Trial Locations (2)

Unknown

Hill Top Research, Scottsdale

Hill Top Research, St. Petersburg

Sponsors
All Listed Sponsors
lead

Somerset Pharmaceuticals

INDUSTRY